Pfizer BioNtech vaccine
A decision is expected next month by European Health Regulators on the use of the Pfizer BioNtech Covid-19 vaccine on children under 12.
The EMA is examining an application to authorise its use on children, aged 5 to 11.
Marco Cavaleri of the EMA, says a decision should be made in December unless additional data is needed:
#Comirnaty for children aged 5 to 11: conclusion expected in December. This is a shortened timetable compared to similar reviews. We will also consider further data collected and submitted by BioNTech/Pfizer from an ongoing paediatric trial. #EMAPresser
— EU Medicines Agency (@EMA_News) November 4, 2021
Yesterday it was announced children as young as 5 will be offered Covid-19 vaccinations in the United States.
The Centres for Disease Control and Prevention recommended the rollout of the Pfizer-BioNtech vaccine, to children aged 5 - 11.
The recommendation will now expand vaccine access to approximately 28 million children in the US.
Vaccinations can begin immediately.
Children under 12 will receive a paediatric dose, which is one third the dosage of an adult vaccine.
Following The US Passenger Jet And Military Helicopter Collision In Washington, US Official's Say Warnings Were Sent
The Gaza Ceasefire Is Now In Effect
